Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Sheraton Silver Spring

Oct 09, 2018 7:30 AM - Oct 10, 2018 5:15 PM

8777 Georgia Ave, Silver Spring, MD 20910

Complex Drug-Device Generic Combination Products Meeting


Co-sponsored with the FDA.

Complex Generic Drugs are a large and diverse group of products with complex active ingredients or sites of action and complex drug-device combination products. They provide important therapies to patients, for example, metered dose inhalers for treating asthma and drugs administered by auto-injectors and prefilled syringes. Because this diverse collection of drug products has one or more elements that are more complex than a simple dosage form, new complexities in the methodologies used for establishing bioequivalence are introduced, thus impeding patient access to the more affordable generic versions of these life-saving medicines.

In 2017, the FDA announced the Drug Competition Action Plan to advance new policies aimed at bringing more competition to the drug market to help reduce drug prices and improve consumer access to these much-needed medicines. The intent is to improve the efficiency of the generic drug approval process and make it easier to bring generic competition to this important category of branded drugs known as complex drugs.

Knowing that the scientific and regulatory pathways for approval of generic versions of complex products are not always well- known to generic developers, FDA intends through its policies to provide as much scientific and regulatory clarity as possible with respect to complex generic drugs. This meeting will address complex drug-device combination products, examining the science of medical device impact on drug bioequivalence in products where the drug is the primary mode of action (PMOA). The impact of devices such as auto injectors, prefilled syringes, inhalant devices, implanted delivery systems, transdermal systems, and others will be explored. The intersections of drug and device regulatory pathways and policies relating to bioequivalence studies will also be reviewed.

Join FDA staff from the CDER Office of Generic Drugs (OGD), the Office of Pharmaceutical Quality (OPQ), CDRH, the Office of Combination Products (OCP), and industry experts to discuss the knowns, unknowns, and the role of modeling in the development of these important products.

NEW! Travel Once, Save Twice!
This year, DIA's Complex Drug-Device Generic Combination Products Meeting will be co-located with DIA's Combination Products Conference. Maximize your education and time by attending both! Save* $100 when you register for both events!
*You must register for both events at the same time for the discount to be applied.

Exclusive Podcast

Take a listen to our podcast with Maryll Toufanian, Acting Director, US FDA Office of Generic Drug Policy. “In order for FDA to approve a generic drug, a generic manufacturer must submit scientific information supporting the generic drug’s ‘sameness’ to the brand.”

Listen In


Additional Resources - On-Demand Generics Webinar Series


Want to learn more about Complex Drug-Device Generic Combination Products Meeting? You've come to the right site!


Who should attend?

Professionals involved in:

  • Biopharmaceutical, Device, and Combination Product R&D and Development
  • Generics Development
  • Clinical Research
  • Pharmacology
  • Regulatory Affairs
  • Safety/Pharmacovigilance
  • Quality Assurance and Control
  • Policy
  • Consulting, Legal, Government Affairs
  • Business Development

Learning objectives

At the conclusion of this Meeting, participants should be able to:

  • Explore the statutory framework and associated regulatory and policy considerations for drug-device combination products submitted in an ANDA
  • Identify and address scientific considerations for establishing bioequivalence for different complex drug-device combination delivery methods
  • Identify specific product quality challenges in developing different approaches to drug-device combination product manufacturing to meet sameness in product performance and cGMP requirements
  • Discuss ideas for improving communication and collaboration between industry, academia, and the agency in developing novel methods and standards for assessing the sameness of complex generic drug-device combination products

Program Committee

  • Markham  Luke, MD, PhD
    Markham Luke, MD, PhD Director for Therapeutic Performance, Office of Generic Drugs, CDER
    FDA, United States
  • Andrew A. LeBoeuf, JD, MS
    Andrew A. LeBoeuf, JD, MS Associate Director Regulatory Policy, ONDP, OND, CDER
    FDA, United States
  • Patricia  Love, MD, MBA
    Patricia Love, MD, MBA Deputy Director, Office of Combination Products, OCPP, OC
    FDA, United States
  • Brian  McCormick
    Brian McCormick Vice President - Chief Regulatory Counsel
    Teva Pharmaceuticals, United States
  • John  Peters, MD
    John Peters, MD Deputy Director, Office of Generic Drugs, CDER
    FDA, United States
  • Susan  Rosencrance, PhD
    Susan Rosencrance, PhD Acting Director, Office of Generic Drugs, CDER
    FDA, United States
  • Alan  Stevens, MS
    Alan Stevens, MS Acting Division Director, Division of Drug Delivery, General Hospital and Human
    FDA, United States
  • Roisin  Wallace
    Roisin Wallace Vice President, Head of Global Device Development and Operations
    Viatris, Ireland
  • John  Weiner, JD
    John Weiner, JD Associate Director for Policy, Office of Combination Products, OCPP, OC
    FDA, United States
  • Kimberly A. Witzmann, MD
    Kimberly A. Witzmann, MD Acting Deputy Director, Office of Bioequivalence, Office of Generic Drugs, CDER
    FDA, United States
  • Jason  Woo, MD, MPH
    Jason Woo, MD, MPH Senior Consultant, Health Care Solutions
    Arbinger Institute, United States
  • Geoffrey  Wu, PhD
    Geoffrey Wu, PhD Deputy Director, Office of Lifecycle Drug Products, OPQ, CDER, FDA
    FDA, United States
  • Lei  Zhang, PhD
    Lei Zhang, PhD Deputy Director, Office of Research & Standards, Office of Generic Drugs, CDER
    FDA, United States

Digital Learning Catalog

DIA Learning: eLearning Soultions

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.